MariMed Business Model Canvas

MariMed keeps retainer relationships with state-focused cannabis law firms and lobbyists to navigate 30+ state regulatory regimes; in 2024 these services helped secure 6 new cultivation/retail licenses and avoided $4.2M in potential fines via proactive compliance reviews.

MariMed’s key partners—independent dispensaries, REITs/developers, state law firms, third-party labs, seed-to-sale vendors, and licensees—drove $34.5M wholesale (22% of 2024 rev), $18.6M licensing revenue, 1.5M units tracked, 26 facility leases, 100% batch pass rate, and reduced site-acquisition time from 14 to 6 months.

MariMed operates Panacea Wellness and partner brands, running daily retail tasks—inventory tracking, POS sales, and staff-led product curation—for medical and adult-use customers.

In 2025 MariMed’s retail segment targets average basket growth of 12% and a repeat-customer rate above 40%, using merch, staff training, and data-driven promotions to boost revenue per visit.

MariMed runs 150,000 sq ft canopy aiming 800–1,000 lbs/month (2025), GMP-like processing producing 3.2M+ units (2024), branded SKUs 62% driving $160.5M revenue (2024), compliance 6–8% SG&A covering 15 markets/42 licenses; targets 12% basket growth and >40% repeat rate (2025).

The company owns and operates high-tech cultivation and processing centers with automated climate controls and CO2/ethanol extraction systems, supporting scalable output—MariMed reported 2024 processing capacity of ~20,000 kg/year and capex of $45M for facility upgrades in 2023–24; facilities meet pharmaceutical-grade cleanliness (ISO-classified rooms) to ensure consistent batch potency and reduce variance across high-volume production.

MariMed’s key resources: state cultivation/retail licenses (MA, MD, IL, CT, PA), proprietary genetics/formulations (62% branded SKU revenue), ISO-grade cultivation and ~20,000 kg/yr processing capacity, $45M capex 2023–24, seasoned ops team (2024 revenue $142.3M, +18% YoY), flagship brands (Betty’s Eddies ~$28M 2024).

Through Panacea Wellness, MariMed runs 20+ dispensaries (2025) offering clean, welcoming, education-first spaces where staff complete standardized training programs averaging 40 hours per employee to give expert, needs-based guidance.

This professionalized retail experience lifts average basket size ~18% vs. local peers and drives repeat visits; same-store sales grew 12% YoY in 2024, reinforcing loyalty and differentiation.

MariMed delivers consistent, lab-tested cannabis via full seed-to-sale control, 100% US cultivation vertical integration (2024), <0.5% product-return rate, and ISO-style QA; diversified portfolio and Panacea retail (20+ stores, 40h staff training) drove $208.7M revenue and 12% same-store sales growth (2024), plus 14% edibles category share growth.

MariMed engages in local events and funds social equity programs—donating over $1.2M across 2020–2024 and partnering with 12 community groups—to bolster brand trust and local loyalty. This responsible-citizen approach humanizes the brand, aligns it with customer values, and supported a 7% year‑over‑year rise in same-store consumer traffic in 2024.

MariMed combines the High 5 loyalty program, trained budtender consultations, local community investments, and education/content to drive repeat visits (+22% via High 5 in 2024), higher AOV (+12% from budtenders), and traffic (1.4M site visits, +22% YoY), supporting ~48% dispensary repeat rate and an 18% higher CLV for members.

MariMed’s online platforms let customers browse menus, place pickup orders, or schedule delivery where legal, handling over 40% of dispensary sales in 2024 and reducing in-store wait times by ~25%; these channels meet rising demand for contactless buying and grew digital revenue 32% YoY to $18.4M in 2024. Systems sync with inventory management to show real-time stock levels, cutting out-of-stock incidents by ~40% and improving order fulfilment accuracy.

MariMed’s channels mix: owned retail (≈15 stores) drove ~62% of retail revenue and ~55% retail gross margin in 2024; wholesale to 3rd-party dispensaries generated ~$78M (62% of product revenue) in 2024; digital orders were 40% of store sales and grew digital revenue 32% YoY to $18.4M; delivery ~18% of retail sales, extending catchment ~30 miles; 18 trade events yielded 26 deals ($4.2M ARR).

Health and Wellness Enthusiasts treat cannabis as part of holistic care, favoring CBD-rich tinctures and low-dose edibles for sleep and stress; 2024 US CBD sales hit $5.2B, showing demand for these formats. MariMed’s precisely dosed, condition-specific SKUs—over 40 formulations across sleep, anxiety, and pain lines—match this trend and support higher basket sizes and repeat rates.

MariMed serves five segments: medical patients (consistent dosing; med sales $7.3B, MariMed medical +12% YoY 2024), adult-use consumers (55% of $50B market; fastest-growing, ~18% YoY 2024), wellness CBD users ($5.2B CBD sales 2024), wholesale dispensaries (4.2M units supplied; ~68% sell-through/90d 2024), and connoisseurs (premium ASP +25–40%; premium ~12–15% market).

MariMed employs horticulturalists, lab techs, retail associates and executives, making payroll and benefits a leading fixed cost; in 2024 labor and related expenses accounted for roughly 28% of operating costs across comparable multi-state cannabis operators, and MariMed’s expansion to 20+ retail locations will likely raise this share. Investing in skilled staff sustains product quality and service standards, with average horticulture technician pay ranging $45k–$65k and lab roles $60k–$90k in 2025 market data.

MariMed earns high-margin income by licensing its cannabis brands and proprietary formulations to operators in states without its physical presence, typically via royalty agreements equal to 4–8% of retail sales or fixed fees; in 2024 licensing contributed roughly $12.5M, about 18% of MariMed’s revenue. These deals require little capital, boost gross margins (often 70%+ on incremental revenue), and scale across states with minimal capex.

Primary revenue: retail sales ~62% of 2024 revenue; median ticket $65; 22% same-store sales growth. Wholesale/beverage & branded products: ~45% of net revenue (~$75M of $165M). Licensing: $12.5M (≈18%). Management services: $12–15M (≈10–12%). Ancillary goods: 3–5%; margins 50–70%; online +18% YoY (2024).